Prediction of fetal blood group and platelet antigens from maternal plasma using next‐generation sequencing

Fetuses whose mothers have produced antibodies to red blood cell (RBC) or platelet antigens are at risk of being affected by hemolytic disease or alloimmune thrombocytopenia, respectively, only if they inherit the incompatible antigen. Noninvasive diagnosis of the fetal antigen is employed for management of immunized pregnancies, but the specific detection of SNPs, encoding the majority of antigens, in maternal plasma is still a challenge. We applied targeted next‐generation sequencing (NGS) to predict the fetal antigen based on the detection of fetomaternal chimerism.

[1]  M. Mikuła,et al.  A preliminary evaluation of next-generation sequencing as a screening tool for targeted genotyping of erythrocyte and platelet antigens in blood donors. , 2018, Blood transfusion = Trasfusione del sangue.

[2]  Y. Liew,et al.  Vox Sanguinis International Forum on application of fetal blood grouping: summary , 2018, Vox sanguinis.

[3]  M. Dębska,et al.  Identification and follow-up of pregnant women with platelet-type human platelet antigen (HPA)-1bb alloimmunized with fetal HPA-1a , 2016, Archives of medical science : AMS.

[4]  C. E. van der Schoot,et al.  Genotyping to prevent Rh disease: has the time come? , 2017, Current opinion in hematology.

[5]  B. Veldhuisen,et al.  Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands , 2016, British Medical Journal.

[6]  Meghan Delaney,et al.  Hemolytic Disease of the Fetus and Newborn: Modern Practice and Future Investigations. , 2016, Transfusion medicine reviews.

[7]  M. Dębska,et al.  14 Years of Polish Experience in Non-Invasive Prenatal Blood Group Diagnosis , 2015, Transfusion Medicine and Hemotherapy.

[8]  A. Bräuninger,et al.  Noninvasive fetal genotyping of human platelet antigen‐1a using targeted massively parallel sequencing , 2015, Transfusion.

[9]  M. Dziegiel,et al.  Next-Generation Sequencing for Antenatal Prediction of KEL1 Blood Group Status. , 2015, Methods in molecular biology.

[10]  A. Tabor,et al.  Pre-Analytical Conditions in Non-Invasive Prenatal Testing of Cell-Free Fetal RHD , 2013, PloS one.

[11]  G. Emons,et al.  Cell‐free fetal DNA in specimen from pregnant women is stable up to 5 days , 2011, Prenatal diagnosis.

[12]  D. Oepkes,et al.  Noninvasive fetal genotyping of human platelet antigen‐1a , 2011, BJOG : an international journal of obstetrics and gynaecology.

[13]  P. Rožman,et al.  Real‐time PCR genotyping of human platelet alloantigens HPA‐1, HPA‐2, HPA‐3 and HPA‐5 is superior to the standard PCR‐SSP method , 2004, Transfusion medicine.

[14]  B. Żupańska,et al.  [Significance of alloantibodies other than anti-D hemolytic disease of the fetus and newborn (HDF/N)]. , 2003, Ginekologia polska.

[15]  I. Sargent,et al.  Presence of fetal DNA in maternal plasma and serum , 1997, The Lancet.